What is AngioDynamics?
Founded in 1988 as a division of E-Z-EM, AngioDynamics has evolved into a critical provider of high-quality medical technology. The company operates at the intersection of clinical efficacy and operational excellence, maintaining a robust global footprint. By focusing on the development of sophisticated medical devices, AngioDynamics addresses complex patient needs, supported by an extensive distribution network and strategic partnerships that facilitate its reach into key international healthcare markets. Its long-standing history serves as a testament to its resilience and ability to adapt to the shifting demands of the medical community.
How much funding has AngioDynamics raised?
AngioDynamics has raised a total of $376.4M across 3 funding rounds:
Stock Offering
$21.4M
Debt
$250M
Debt
$105M
Stock Issuance/Offering (2004): $21.5M, investors not publicly disclosed
Debt (2016): $250M, investors not publicly disclosed
Debt (2022): $105M, investors not publicly disclosed
Key Investors in AngioDynamics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for AngioDynamics?
Looking ahead, the recent capital injection positions AngioDynamics to accelerate its research and development initiatives while optimizing its supply chain for greater efficiency. As the company transitions into its next phase of growth, the focus will likely remain on expanding its footprint in high-growth therapeutic areas. By prioritizing technological advancements and maintaining its strategic partnerships, AngioDynamics is well-equipped to sustain its trajectory as a leader in medical device innovation, ensuring that its financial resources are effectively deployed to enhance patient outcomes and drive long-term shareholder value.
See full AngioDynamics company page
